ESR1 and breast cancer: In addition, improved risk prediction for specific subtypes of breast cancer will permit targeted enrollment of Black women into prevention trials for medications for estrogen receptor (ER)-positive or ER-negative breast cancer to increase the likelihood that medications developed will also benefit Black women.